Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, today announced that Nobel Laureate and Scientific Co-Founder, Rod MacKinnon, M.D., and Chief Executive Officer, Christoph Westphal, M.D., Ph.D., will ring the NASDAQ Stock Market Closing Bell at the NASDAQ MarketSite in Times Square on Monday, June 1, 2015, at 4:00 p.m.
Drs. MacKinnon and Westphal will be joined by members of the Flex Pharma management team, Board of Directors, colleagues and friends to celebrate the progress the Company has made since its initial public offering. Flex Pharma began trading on the NASDAQ Global Market on January 29, 2015.
This event will be broadcast on the major business networks and a live webcast of the NASDAQ Closing Bell can be accessed at https://new.livestream.com/nasdaq/live.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.